Seasonal Malaria Chemoprevention Strategies

Seasonal malaria chemoprevention (SMC) is a public health intervention designed to reduce the burden of Plasmodium falciparum in regions characterised by highly seasonal transmission, primarily across the Sahel of Africa. The approach involves monthly administration of full therapeutic courses of antimalarial drugs—most commonly sulfadoxine-pyrimethamine plus amodiaquine—to children during the high-risk months. This dual function of parasite clearance and post-treatment prophylaxis has demonstrably lowered clinical episodes and hospital admissions for severe malaria. Recent refinements include extending the eligible age range to school-age children, integrating the RTS,S/AS01E vaccine to bolster pre-erythrocytic immunity, and evaluating alternative regimens such as dihydroartemisinin-piperaquine where antifolate resistance threatens efficacy. Operational research emphasises door-to-door and community-based delivery models, rigorous coverage monitoring and adaptive cycle timing to align with local transmission peaks. Modelling studies have further informed the optimisation of dosing schedules and age targets to delay the spread of drug-resistant parasite strains and maximise cost–effectiveness across diverse epidemiological settings.

Research from Nature Portfolio

Evidence from a large prospective cohort in the Gambia demonstrates that extending SMC eligibility from under five to under ten years yields measurable household-level benefits. Older siblings and adults in households where children received additional SMC rounds experienced a 20% reduction in clinical malaria risk for each monthly cycle. High-coverage implementation was linked to diminished asymptomatic carriage among non-eligible members, indicating that age-expanded SMC can shrink the human infectious reservoir and contribute to local transmission interruption when delivered through routine health services.

Seasonal Malaria Chemoprevention Strategies publication trend

The graph below shows the total number of articles in seasonal malaria chemoprevention strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Seasonal malaria chemoprevention (SMC): Prophylactic administration of antimalarial drugs at monthly intervals during high-transmission seasons to vulnerable paediatric groups.

Sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ): A fixed drug combination of antifolate and 4-aminoquinoline agents used in monthly chemoprevention to clear parasitaemia and provide weeks of post-treatment protection.

RTS,S/AS01E vaccine: A recombinant pre-erythrocytic vaccine targeting the circumsporozoite protein of P. falciparum, deployed seasonally to enhance immune protection before peak transmission.

Quintuple mutation: Five specific point mutations in P. falciparum dihydrofolate reductase and dihydropteroate synthase genes that confer high-level resistance to sulfadoxine-pyrimethamine.

References

1. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases (2023).
2. Seasonal malaria chemoprevention and the spread of Plasmodium falciparum quintuple-mutant parasites resistant to sulfadoxine–pyrimethamine: a modelling study. The Lancet Microbe (2024).
3. Household-level effects of seasonal malaria chemoprevention in the Gambia. Communications Medicine (2024).
4. Randomized Field Trial to Assess the Safety and Efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in School-Aged Children in Bandiagara, Mali. The Journal of Infectious Diseases (2023).